Aradigm Corporation Announces Third Quarter 2014 Financial Results
Aradigm Corporation (Nasdaq:ARDM) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2014.
Total revenue was approximately $6.6 million for the third quarter of 2014 compared with revenue of approximately $4.6 million for the third quarter of 2013. Revenue for both periods consisted primarily of revenue from the Grifols collaboration arrangement as the Company is being reimbursed for Pulmaquin® inhaled ciprofloxacin project-related costs.
Help employers find you! Check out all the jobs and post your resume.
Total revenue was approximately $6.6 million for the third quarter of 2014 compared with revenue of approximately $4.6 million for the third quarter of 2013. Revenue for both periods consisted primarily of revenue from the Grifols collaboration arrangement as the Company is being reimbursed for Pulmaquin® inhaled ciprofloxacin project-related costs.
Help employers find you! Check out all the jobs and post your resume.